Hope Medicine Inc., based in China, has announced the first patient dosing in a global Phase II clinical trial for its monoclonal antibody (mAb) HMI-115, which targets the prolactin receptor (PRL R). The study aims to evaluate HMI-115 as a treatment for endometriosis in Chinese patients.
In April 2019, Hope Medicine entered into a licensing agreement with Bayer, the drug’s originator, securing global development and commercialization rights for HMI-115 across multiple indications. The drug is being developed not only for endometriosis but also for androgenic alopecia, having shown promising results in preclinical animal models and human safety trials. HMI-115 has received Phase II clinical trial approvals in both the United States and China.- Flcube.com
